{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:19:20Z","timestamp":1787667560772,"version":"build-2736575974"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40271-026-00804-7","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:28:35Z","timestamp":1773239315000},"page":"637-654","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incorporating the Patient Voice into Attribute and Level Selection for a Preference Study: A Qualitative Study in Non-Muscle Invasive Bladder Cancer"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1979-6788","authenticated-orcid":false,"given":"Brad","family":"Mason","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Eccleston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Ayala-Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Hauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Gater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Coulter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pam","family":"Hallworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Brinkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C.","family":"Cappelleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Chisolm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Satkunasivam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"804_CR1","unstructured":"American Cancer Society. Cancer Statistics Center: National incidence rated by type. https:\/\/cancerstatisticscenter.cancer.org\/#\/. Accessed 6 Nov 2024."},{"issue":"3","key":"804_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"804_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/medsci8010015","volume":"8","author":"K Saginala","year":"2020","unstructured":"Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci. 2020;8(1):15.","journal-title":"Med Sci"},{"issue":"1","key":"804_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"804_CR5","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","volume":"5","author":"N Lobo","year":"2022","unstructured":"Lobo N, Afferi L, Moschini M, et al. Epidemiology, screening, and prevention of bladder cancer. Eur Urol Oncol. 2022;5(6):628\u201339.","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"804_CR6","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000003846","volume":"211","author":"JM Holzbeierlein","year":"2024","unstructured":"Holzbeierlein JM, Bixler BR, Buckley DI, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment. J Urol. 2024;211(4):533\u20138.","journal-title":"J Urol"},{"issue":"5","key":"804_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/MOU.0b013e328356aecf","volume":"22","author":"SP Porten","year":"2012","unstructured":"Porten SP, Cooperberg MR. High-risk nonmuscle invasive bladder cancer: definition and epidemiology. Curr Opin Urol. 2012;22(5):385\u20139.","journal-title":"Curr Opin Urol"},{"issue":"4","key":"804_CR8","first-page":"1659","volume":"24","author":"B Ucpinar","year":"2019","unstructured":"Ucpinar B, Erbin A, Ayranci A, et al. Prediction of recurrence in non-muscle invasive bladder cancer patients. Do patient characteristics matter? J BOUN. 2019;24(4):1659\u201365.","journal-title":"J BOUN"},{"key":"804_CR9","unstructured":"Cancer Council Victoria. Bladder Cancer. https:\/\/www.cancervic.org.au\/cancer-information\/types-of-cancer\/bladder_cancer\/treatment-non-invasive-bladder-cancer.html#:~:text=The%20main%20treatments%20for%20non,bladder%20tumour%20(TURBT)%20operation. Accessed 17 Sept 2024."},{"key":"804_CR10","unstructured":"National Comprehensive Cancer Network I. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Bladder Cancer V.6.2021. https:\/\/www.nccn.org\/guidelines. Accessed 17 Sept 2024."},{"issue":"4","key":"804_CR11","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124\u20139.","journal-title":"J Urol"},{"issue":"1","key":"804_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81(1):75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010.","journal-title":"Eur Urol"},{"issue":"4","key":"804_CR13","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol. 2016;196(4):1021\u20139.","journal-title":"J Urol"},{"issue":"13","key":"804_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133073","volume":"14","author":"S Jiang","year":"2022","unstructured":"Jiang S, Redelman-Sidi G. BCG in bladder cancer immunotherapy. Cancers. 2022;14(13):3073.","journal-title":"Cancers"},{"key":"804_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1170124","volume":"13","author":"K Grabe-Heyne","year":"2023","unstructured":"Grabe-Heyne K, Henne C, Mariappan P, Geiges G, P\u00f6hlmann J, Pollock RF. Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Front Oncol. 2023;13:1170124. https:\/\/doi.org\/10.3389\/fonc.2023.1170124.","journal-title":"Front Oncol"},{"issue":"5","key":"804_CR16","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"RJ Sylvester","year":"2010","unstructured":"Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette\u2013Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010;57(5):766\u201373. https:\/\/doi.org\/10.1016\/j.eururo.2009.12.024.","journal-title":"Eur Urol"},{"issue":"4","key":"804_CR17","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance Bacillus Calmette\u2013Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124\u20139.","journal-title":"J Urol"},{"issue":"2","key":"804_CR18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4103\/UA.UA_29_19","volume":"12","author":"NK Gupta","year":"2020","unstructured":"Gupta NK, Sarkar D, Pal DK. Monthly maintenance protocol Bacillus Calmette\u2013Guerin as a viable alternative to Southwest Oncology Group maintenance protocol in nonmuscle-invasive bladder cancer: a prospective randomized study. Urol Ann. 2020;12(2):116.","journal-title":"Urol Ann"},{"key":"804_CR19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ijsu.2018.02.045","volume":"52","author":"S Chen","year":"2018","unstructured":"Chen S, Zhang N, Shao J, Wang X. Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized clinical trials. Int J Surg. 2018;52:248\u201357.","journal-title":"Int J Surg"},{"key":"804_CR20","volume-title":"Patient experience and unmet needs in high-risk nonmuscle-invasive bladder cancer: insights from qualitative interviews and a cross-sectional survey","author":"L Kopenhafer","year":"2024","unstructured":"Kopenhafer L, Thompson A, Chang J, et al. Patient experience and unmet needs in high-risk nonmuscle-invasive bladder cancer: insights from qualitative interviews and a cross-sectional survey. Amsterdam: Elsevier; 2024."},{"issue":"10","key":"804_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101843","volume":"16","author":"S McNall","year":"2024","unstructured":"McNall S, Hooper K, Sullivan T, Rieger-Christ K, Clements M. Treatment modalities for non-muscle invasive bladder cancer: an updated review. Cancers. 2024;16(10):1843.","journal-title":"Cancers"},{"key":"804_CR22","volume-title":"Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: the evolving role of PD-(L) 1 inhibition","author":"J Bedke","year":"2023","unstructured":"Bedke J, Black PC, Szabados B, et al. Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: the evolving role of PD-(L) 1 inhibition. Amsterdam: Elsevier; 2023."},{"key":"804_CR23","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","volume":"31","author":"ND Shore","year":"2025","unstructured":"Shore ND, Powles TB, Bedke J, et al. Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. Nat Med. 2025;31:2806\u201314. https:\/\/doi.org\/10.1038\/s41591-025-03738-z.","journal-title":"Nat Med"},{"issue":"10516","key":"804_CR24","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","volume":"406","author":"M De Santis","year":"2025","unstructured":"De Santis M, Redorta JP, Nishiyama H, et al. Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. Lancet. 2025;406(10516):2221\u201334.","journal-title":"Lancet"},{"key":"804_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.03.007","author":"M Longoni","year":"2025","unstructured":"Longoni M, Scilipoti P, Soria F, et al. Oncological outcomes in BacillusCalmette-Gu\u00e9rin\u2013na\u00efve high-risk non\u2013muscle-invasive bladder cancer patients: a systematic review on current treatment strategies and future perspectives. Eur Urol Oncol. 2025. https:\/\/doi.org\/10.1016\/j.euo.2025.03.007.","journal-title":"Eur Urol Oncol"},{"key":"804_CR26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.euros.2022.12.016","volume":"49","author":"H Collacott","year":"2023","unstructured":"Collacott H, Krucien N, Heidenreich S, Catto JWF, Ghatnekar O. Patient preferences for treatment of Bacillus Calmette\u2013Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer: a cross-country choice experiment. Eur Urol Open Sci. 2023;49:92\u20139. https:\/\/doi.org\/10.1016\/j.euros.2022.12.016.","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"804_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.drudis.2018.09.015","volume":"24","author":"E van Overbeeke","year":"2019","unstructured":"van Overbeeke E, Whichello C, Janssens R, et al. Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review. Drug Discov Today. 2019;24(1):57\u201368. https:\/\/doi.org\/10.1016\/j.drudis.2018.09.015.","journal-title":"Drug Discov Today"},{"issue":"3","key":"804_CR28","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jval.2019.12.005","volume":"23","author":"HL Benz","year":"2020","unstructured":"Benz HL, Saha A, Tarver ME. Integrating the voice of the patient into the medical device regulatory process using patient preference information. Value Health. 2020;23(3):294\u20137.","journal-title":"Value Health"},{"key":"804_CR29","unstructured":"Patient preference information\u2014voluntary submission, review in premarket approval applications, humanitarian device exemption applications, and de novo requests, and inclusion in decision summaries and device labeling. guidance for industry, Food and Drug Adminsitration staff and other stakeholders (Office of Communication, outreach and Development) (2016)."},{"key":"804_CR30","unstructured":"Food and Drug Administration (FDA). Patient-focused drug development: collecting comprehensive and representative input\u2014guidance for industry, Food and Drug Administration staff, and other stakeholders. 2020. https:\/\/www.fda.gov\/media\/139088\/download."},{"key":"804_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.05.014","author":"NG Bohorquez","year":"2024","unstructured":"Bohorquez NG, Malatzky C, McPhail SM, Mitchell R, Lim MHA, Kularatna S. Attribute development in health-related discrete choice experiments: a systematic review of qualitative methods and techniques to inform quantitative instruments. Value Health. 2024. https:\/\/doi.org\/10.1016\/j.jval.2024.05.014.","journal-title":"Value Health"},{"issue":"5","key":"804_CR32","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40271-022-00581-z","volume":"15","author":"D Barthold","year":"2022","unstructured":"Barthold D, Brah AT, Graham SM, Simoni JM, Hauber B. Improvements to survey design from pilot testing a discrete-choice experiment of the preferences of persons living with HIV for long-acting antiretroviral therapies. Patient. 2022;15(5):513\u201320. https:\/\/doi.org\/10.1007\/s40271-022-00581-z.","journal-title":"Patient"},{"issue":"3","key":"804_CR33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40271-024-00677-8","volume":"17","author":"J Coulter","year":"2024","unstructured":"Coulter J, Whichello C, Heidenreich S, et al. From qualitative research to quantitative preference elicitation: an example in invasive meningococcal disease. Patient. 2024;17(3):319\u201333. https:\/\/doi.org\/10.1007\/s40271-024-00677-8.","journal-title":"Patient"},{"key":"804_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40271-019-00401-x","volume":"13","author":"IL Hollin","year":"2020","unstructured":"Hollin IL, Craig BM, Coast J, et al. Reporting formative qualitative research to support the development of quantitative preference study protocols and corresponding survey instruments: guidelines for authors and reviewers. Patient. 2020;13:121\u201336.","journal-title":"Patient"},{"issue":"6","key":"804_CR35","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3109\/14659891.2015.1118563","volume":"21","author":"TM Helter","year":"2016","unstructured":"Helter TM, Boehler CE. Developing attributes for discrete choice experiments in health: a systematic literature review and case study of alcohol misuse interventions. J Subst Use. 2016;21(6):662\u20138. https:\/\/doi.org\/10.3109\/14659891.2015.1118563.","journal-title":"J Subst Use"},{"key":"804_CR36","first-page":"372","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:372.","journal-title":"BMJ"},{"key":"804_CR37","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.6470922","author":"The PREFER consortium","year":"2022","unstructured":"The PREFER consortium. PREFER recommendations: why, when and how to assess and use patient preferences in medical product decision-making. 2022. Zenodo. https:\/\/doi.org\/10.5281\/zenodo.6470922."},{"issue":"2","key":"804_CR38","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40271-024-00672-z","volume":"17","author":"NB Campoamor","year":"2024","unstructured":"Campoamor NB, Guerrini CJ, Brooks WB, Bridges JF, Crossnohere NL. Pretesting discrete-choice experiments: a guide for researchers. Patient. 2024:17(2):109\u201320.","journal-title":"Patient"},{"issue":"4","key":"804_CR39","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JF Bridges","year":"2011","unstructured":"Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403\u201313. https:\/\/doi.org\/10.1016\/j.jval.2010.11.013.","journal-title":"Value Health"},{"issue":"2","key":"804_CR40","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jval.2022.12.004","volume":"26","author":"JFP Bridges","year":"2023","unstructured":"Bridges JFP, de Bekker-Grob EW, Hauber B, et al. A roadmap for increasing the usefulness and impact of patient-preference studies in decision making in health: a good practices report of an ISPOR Task Force. Value Health. 2023;26(2):153\u201362. https:\/\/doi.org\/10.1016\/j.jval.2022.12.004.","journal-title":"Value Health"},{"key":"804_CR41","unstructured":"Food and Drug Administration (FDA). Patient preference information\u2014voluntary submission, review in premarket approval applications, humanitarian device exemption applications, and de novo requests, and inclusion in decision summaries and device labeling. Guidance for industry, Food and Drug Adminsitration staff and other stakeholders. 2016."},{"key":"804_CR42","unstructured":"Food and Drug Administration (FDA). Patient-Focused drug development: methods to identify what is important to patients - guidance for industry, Food and Drug Administration staff, and other stakeholders. https:\/\/www.fda.gov\/media\/131230\/download. Accessed 17 Sept 2024."},{"key":"804_CR43","unstructured":"Food and Drug Administration (FDA). Incorporating voluntary patient preference information over the total product life cycle. draft guidance for industry, Food and Drug Administration staff, and other interested parties. Accessed October, 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/incorporating-voluntary-patient-preference-information-over-total-product-life-cycle"},{"issue":"1","key":"804_CR44","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18(1):59\u201382.","journal-title":"Field Methods"},{"issue":"7","key":"804_CR45","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","volume":"21","author":"DM Turner-Bowker","year":"2018","unstructured":"Turner-Bowker DM, Lamoureux RE, Stokes J, et al. Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health. 2018;21(7):839\u201342. https:\/\/doi.org\/10.1016\/j.jval.2017.11.014.","journal-title":"Value Health"},{"issue":"9","key":"804_CR46","first-page":"1408","volume":"20","author":"PI Fusch","year":"2015","unstructured":"Fusch PI, Ness LR. Are we there yet? Data saturation in qualitative research. Qual Rep. 2015;20(9):1408\u201316.","journal-title":"Qual Rep"},{"key":"804_CR47","unstructured":"ATLAS.ti software. Windows (version 22.2.5). 2022."},{"issue":"2","key":"804_CR48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"issue":"9","key":"804_CR49","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"H-F Hsieh","year":"2005","unstructured":"Hsieh H-F, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277\u201388.","journal-title":"Qual Health Res"},{"issue":"1","key":"804_CR50","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1177\/160940690600500107","volume":"5","author":"J Fereday","year":"2006","unstructured":"Fereday J, Muir-Cochrane E. Demonstrating rigor using thematic analysis: a hybrid approach of inductive and deductive coding and theme development. Int J Qual Methods. 2006;5(1):80\u201392.","journal-title":"Int J Qual Methods"},{"key":"804_CR51","unstructured":"US Department of Health and Human Services NIoH, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5. 2017. November 27."},{"key":"804_CR52","unstructured":"European Medicines Agency (EMA). Reflection paper on patient experience data (DRAFT). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-patient-experience-data_en.pdf. Accessed 17 Sept 2024."},{"key":"804_CR53","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-024-00673-y","author":"AC M\u00fchlbacher","year":"2024","unstructured":"M\u00fchlbacher AC, de Bekker-Grob EW, Rivero-Arias O, Levitan B, Vass C. How to present a decision object in health preference research: attributes and levels, the decision model, and the descriptive framework. Patient Patient Cent Outcomes Res. 2024. https:\/\/doi.org\/10.1007\/s40271-024-00673-y.","journal-title":"Patient Patient Cent Outcomes Res"},{"key":"804_CR54","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.euros.2022.12.016","volume":"49","author":"H Collacott","year":"2023","unstructured":"Collacott H, Krucien N, Heidenreich S, Catto JW, Ghatnekar O. Patient preferences for treatment of Bacillus Calmette\u2013Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer: a cross-country choice experiment. Eur Urol Open Sci. 2023;49:92\u20139.","journal-title":"Eur Urol Open Sci"},{"issue":"6","key":"804_CR55","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40271-021-00520-4","volume":"14","author":"H Collacott","year":"2021","unstructured":"Collacott H, Soekhai V, Thomas C, et al. A systematic review of discrete choice experiments in oncology treatments. Patient. 2021;14(6):775\u201390.","journal-title":"Patient"},{"key":"804_CR56","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-024-00725-3","author":"M Picci","year":"2025","unstructured":"Picci M, Cook NS, Jones B, et al. Designing a patient preference study on subcutaneous medical devices: incorporating health authority scientific advice and patient perspectives. Ther Innov Regul Sci. 2025. https:\/\/doi.org\/10.1007\/s43441-024-00725-3.","journal-title":"Ther Innov Regul Sci"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00804-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-026-00804-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00804-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:26:43Z","timestamp":1787664403000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-026-00804-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["804"],"URL":"https:\/\/doi.org\/10.1007\/s40271-026-00804-7","relation":{"references":[{"id-type":"doi","id":"10.5281\/zenodo.6470922","asserted-by":"subject"}]},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was funded by Pfizer Inc. The study was conducted by Adelphi Values Patient-Centered Outcomes under the direction of Pfizer Inc. BM, LA, and AG are employees of Adelphi Values Patient-Centered Outcomes, and PH and BB are employees of Adelphi Research, who received consulting fees from Pfizer to conduct this study and for the development of this manuscript. AE, BH, JC, AT, JC, JB, and JCC are employees of Pfizer and hold stock options or ownership interest in Pfizer. RS is an employee of Houston Methodist Hospital, who received consulting fees from Pfizer to provide expertise and support for the conduct of this study and for the development of this manuscript. SC is an employee of Bladder Cancer Advocacy Network (BCAN), who received consulting fees from Pfizer to provide expertise and support for the conduct of this study and for the development of this manuscript. No other disclosures were reported.","order":1,"name":"Ethics","label":"Conflicts of interest, funding, or competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Participants provided wet and digitally collected written consent.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All relevant data has been reported in the manuscript body and electronic supplementary material. The individual participant datasets generated during and\/or analyzed in this study are not publicly available due to research participants consenting to data being published in anonymized format and interview recordings\/transcripts only being available to the project teams responsible for conducting and\/or analyzing the research.","order":3,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the conception and design of the research. BM and LA conducted the targeted literature review, the qualitative interviews, and acquired the data. BM and LA analyzed the qualitative data. All authors contributed to data interpretation and updates to the attributes and levels. All authors approved the version to be published and agree to be accountable for all aspects of the research.","order":4,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}